Skip to Content
Merck
All Photos(1)

Key Documents

A9730

Sigma-Aldrich

Adefovir dipivoxil

Synonym(s):

9-(2[bis(Pivaloyloxymethoxy)phosphorylmethoxy]ethyl)adenine

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C20H32N5O8P
CAS Number:
Molecular Weight:
501.47
MDL number:
UNSPSC Code:
51102829
PubChem Substance ID:
NACRES:
NA.76

biological source

synthetic

Quality Level

Assay

≥98% (HPLC)

form

solid

solubility

ethanol: 50 mg/mL

antibiotic activity spectrum

viruses

Mode of action

enzyme | inhibits

storage temp.

−20°C

SMILES string

CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C

InChI

1S/C20H32N5O8P/c1-19(2,3)17(26)30-11-32-34(28,33-12-31-18(27)20(4,5)6)13-29-8-7-25-10-24-14-15(21)22-9-23-16(14)25/h9-10H,7-8,11-13H2,1-6H3,(H2,21,22,23)

InChI key

WOZSCQDILHKSGG-UHFFFAOYSA-N

Biochem/physiol Actions

Adefovir is an antiviral acyclic nucleoside phosphonate (ANP) analog that works by blocking reverse transcriptase. It is an inhibitor of duck hepatitis B virus (DHBV) replication that inhibits covalently closed circular DNA (CCC DNA) amplification. Cytotxicity is induced by Human Renal Organic Anion Transporter 1 (hOAT1). Adefovir is an Inhibitor of edema factor (EF)-induced cAMP accumulation and changes in cytokine production in mouse primary macrophages .

Other Notes

Keep container tightly closed in a dry and well-ventilated place.

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Baek Gyu Jun et al.
PloS one, 13(7), e0201316-e0201316 (2018-07-31)
Convincing data that support routine use of preventive therapy against hepatitis B virus (HBV) reactivation in radiotherapy (RT) for hepatocellular carcinoma (HCC) are lacking. The aim of this study was to investigate the incidence, clinical significance, and risk factors of
Julien Delmas et al.
Antimicrobial agents and chemotherapy, 46(2), 425-433 (2002-01-18)
The elimination of viral covalently closed circular DNA (CCC DNA) from the nucleus of infected hepatocytes is an obstacle to achieving sustained viral clearance during antiviral therapy of chronic hepatitis B virus (HBV) infection. The aim of our study was
F Stelma et al.
Journal of viral hepatitis, 24(12), 1107-1113 (2017-06-21)
Combining peginterferon-alfa-2a (pegIFN) with a nucleotide analogue can result in higher rates of HBsAg loss than either therapy given alone. Here, we investigated the durability of the response to combination therapy in chronic hepatitis B (CHB) patients after 5 years of
M Danta et al.
International journal of clinical practice, 58(9), 877-886 (2004-11-09)
Adefovir dipivoxil (ADF) is a novel acyclic nucleoside analogue that has recently been approved for the treatment of chronic hepatitis B virus (HBV). Adefovir was initially assessed at higher doses for the treatment of human immunodeficiency virus (HIV) infection. However
A Takeda et al.
Journal of viral hepatitis, 14(2), 75-88 (2007-01-25)
Standard treatments for chronic hepatitis B (CHB) include interferon-alpha (IFN-alpha) and lamivudine (LAM), but these are associated with adverse effects and viral resistance, respectively. The aim of this systematic review and economic evaluation was to assess the clinical effectiveness and

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service